01 / 20

Chronic Coronary
Disease Management

A practical approach to stable ischemic heart disease: lifestyle, medications that prolong life, and when to revascularize.

USMLE Step 3

What Is Chronic Coronary Disease?

Chronic coronary disease (CCD), also called stable ischemic heart disease, is a long-standing condition in which fixed atherosclerotic plaque narrows the coronary arteries. The result is a mismatch between myocardial oxygen supply and demand during exertion.

The Supply–Demand Mismatch

Oxygen Supply Coronary blood flow Diastolic time O₂ content (Hb, SaO₂) ↓ by plaque Oxygen Demand Heart rate Contractility Wall stress ↑ by exertion
\( \text{Demand} > \text{Supply} \rightarrow \text{Ischemia (angina)} \)

Two Goals of Therapy

1. Prolong Survival
Prevent MI and death. Achieved by aspirin, statins, ACE inhibitors/ARBs, and risk-factor control. These reduce events.
2. Relieve Symptoms
Reduce angina and improve quality of life. Achieved by β-blockers, nitrates, calcium-channel blockers, ranolazine.

Core Rule: Optimal Medical Therapy First

The ISCHEMIA and COURAGE trials showed that in stable patients, an initial invasive strategy did not reduce death or MI compared to optimal medical therapy. PCI relieves angina but does not prolong life in stable disease.

The ABCDE Framework

A
Antiplatelet & Antianginal. Aspirin 81 mg daily; β-blocker / nitrate for symptoms.
B
Blood pressure & β-blocker. Target \( \text{BP} < 130/80 \); β-blocker first-line antianginal.
C
Cholesterol & Cigarettes. High-intensity statin; complete smoking cessation.
D
Diet & Diabetes. Mediterranean diet; SGLT2 inhibitor / GLP-1 if diabetic.
E
Exercise & Education. Cardiac rehab; 150 min/week moderate activity.

Distinction: Stable vs Acute Coronary Syndrome

Stable Angina (CCD)Acute Coronary Syndrome
TriggerPredictable exertionAt rest / crescendo
ReliefRest or nitroglycerinOften not relieved by rest
TroponinNormalMay be elevated
PathologyFixed plaquePlaque rupture, thrombus
DispositionOutpatient GDMTEmergent, admit

How to Approach a CCD Patient

1
Confirm diagnosis & risk. Characterize angina, assess pretest probability, stress test if needed.
2
Start mortality-benefit drugs. Aspirin, high-intensity statin, ACEi/ARB if diabetes/HTN/LV dysfunction.
3
Add antianginal therapy. β-blocker first; add nitrate or CCB if symptoms persist.
4
Reassess. Refractory angina or high-risk anatomy → consider revascularization.

Drugs That Prolong Life

Aspirin ↓ thrombosis Statin ↓ LDL, plaque stable ACEi / ARB if DM/HTN/LVEF↓ ↓ MI and Death Survival benefit

Lipid Targets: High-Intensity Statin

All CCD patients are in a secondary prevention group. Start a high-intensity statin aiming for at least a 50% LDL reduction. Goal: \( \text{LDL-C} < 70 \) mg/dL, and many guidelines now target \( \text{LDL-C} < 55 \) mg/dL in very high-risk patients.

Worked Example: New Diagnosis

1
Mortality drugs: aspirin 81 mg, high-intensity statin.
2
Antianginal: start a β-blocker; sublingual nitroglycerin PRN.
3
Risk factors: intensive smoking cessation, BP control.

Worked Example: Refractory Angina

1
Confirm GDMT optimized — adequate doses of antianginals already in use.
2
Symptoms refractory despite maximal therapy → coronary angiography.
3
Revascularize (PCI or CABG) to relieve disabling angina.

Worked Example: PCI or CABG?

PCI 1–2 vessel disease No diabetes CABG ★ Multivessel + DM Low EF, LAD disease

Common Mistakes

✕ PCI prolongs life
In stable CCD, PCI relieves angina but does not reduce death or MI versus GDMT.
✕ Skipping the statin
Every CCD patient needs a high-intensity statin regardless of baseline LDL.
✕ Forgetting cessation
Smoking cessation is one of the highest-yield interventions and is often overlooked.
✕ Cath everyone first
Optimal medical therapy comes before routine angiography in stable patients.

Summary: Drug Roles

Drug ClassSurvivalSymptoms
AspirinYesNo
High-intensity statinYesNo
ACEi / ARB (DM, HTN, low EF)YesNo
β-blockerYes (post-MI)Yes
NitratesNoYes
CCB / RanolazineNoYes

Question 1 of 5

A 62-year-old man with stable angina is started on therapy. Which medication is given primarily to reduce mortality, not symptoms?

Question 2 of 5

A stable CCD patient with single-vessel reversible ischemia asks if a stent will help him "live longer." What is the best response?

Question 3 of 5

Which first-line antianginal also provides a mortality benefit in patients with a prior myocardial infarction?

Question 4 of 5

A diabetic patient with refractory angina has three-vessel disease, a proximal LAD lesion, and \( \text{LVEF} = 30\% \). Which revascularization is preferred?

Question 5 of 5

A CCD patient on a maximally tolerated statin still has \( \text{LDL-C} = 95 \) mg/dL. What is the best next step?